Sorrento Therapeutics is making strides in its development of new treatments for cancer, inflammation, and autoimmune diseases. The California-based biopharmaceutical company is focused on antibodies, with multiple late-stage biosimilar and biobetter antibody products, as well as clinical CAR-T therapies targeting solid tumors, in its pipeline. With a broad foundation in antibody research and development, Sorrento is poised to be a strong contender in the biopharmaceutical market.